<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00431041</url>
  </required_header>
  <id_info>
    <org_study_id>VES-001</org_study_id>
    <nct_id>NCT00431041</nct_id>
  </id_info>
  <brief_title>Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)</brief_title>
  <acronym>VECTOR</acronym>
  <official_title>VECTOR: A Randomized Double-blind Study to Assess the Safety and Efficacy of Solifenacin (Vesicare®) in Comparison to Oxybutynin for Overactive Bladder Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Canada, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of solifenacin with
      oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective randomized, double-blind, double-dummy, multicentre, 2-arm (1
      Active, Active Control) comparative parallel group study to compare the safety and efficacy
      of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder
      (OAB).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Subjects Reporting Incidence of Dry Mouth as an Adverse Event</measure>
    <time_frame>8 weeks</time_frame>
    <description>The number of subjects reporting incidence of dry mouth as an adverse event (AE) following direct questioning at each patient follow-up visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Severity of Dry Mouth Reported as an Adverse Event</measure>
    <time_frame>8 weeks</time_frame>
    <description>The number of subjects reporting dry mouth at each severity level when dry mouth was reported as an Adverse Event (AE).
Dry mouth severity was categorized as &quot;mild&quot; (relieved with fluid/hard candy), &quot;moderate&quot; (dry mouth and throat with no difficulty swallowing solid food/water) &amp; &quot;severe&quot; (very dry mouth &amp; throat, difficulty swallowing solid food without water)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Micturition Frequency as Reported in Subject 3-day Diary</measure>
    <time_frame>Baseline and 8 Weeks</time_frame>
    <description>Subjects were instructed to complete the diary in the 3 day period immediately proceding the visit. Subjects recorded each micturition or instance of passing urine in the toliet.
The mean was calculated for each time point as the average of the day 1-3 measurements from the associated 3 day diary. Change from baseline was calculated as Week 8- Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urgency Episodes as Reported in Subject 3-day Diary</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Subjects were instructed to complete the diary in the 3 day period immediately preceding the visit. Subjects recorded each urgency episode or instance of strong desire to pass urine.
The mean was calculated for each time point as the average of the day 1-3 measurements from the associated 3 day diary. Change from Baseline was calculated as Week 8- Baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Solifenacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solifenacin succinate: 5 mg tablets, taken orally, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxybutynin IR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxybutynin Immediate Release: 5 mg capsules, taken orally, 3 times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>solifenacin</intervention_name>
    <description>Oral</description>
    <arm_group_label>Solifenacin</arm_group_label>
    <other_name>VESIcare®</other_name>
    <other_name>YM905</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxybutynin immediate release</intervention_name>
    <description>Oral</description>
    <arm_group_label>Oxybutynin IR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 18 years and older.

          -  Overactive bladder symptoms for greater than or equal to 3 months and as documented in
             a 3-day patient diary following screening and preceding baseline visit: &gt; 1 urge
             episodes/24 hours (average); greater than or equal to 8 micturitions/24 hours
             (average)

        Exclusion Criteria:

          -  Urinary tract infection, chronic inflammation such as interstitial cystitis and
             bladder stones

          -  Clinically significant outflow obstruction

          -  Uncontrolled narrow angle glaucoma, urinary, or gastric retention

          -  Severe renal or hepatic impairment

          -  Chronic severe constipation or history of diagnosed GI obstructive disease

          -  Significant stress incontinence or mixed stress/urge incontinence where stress is the
             predominant factor

          -  Diagnosis or history of neurogenic bladder

          -  History of bladder or pelvic cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Canada, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2V 4R6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H 3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T 5G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guelph</city>
        <state>Ontario</state>
        <zip>N1H 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2N 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6A 3B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.astellas.com/ca/media/pdf/Vesicare_Product_Monograph.pdf</url>
    <description>Link to prescribing information</description>
  </link>
  <reference>
    <citation>Herschorn S, Stothers L, Carlson K, Egerdie B, Gajewski JB, Pommerville P, Schulz J, Radomski S, Drutz H, Barkin J, Paradiso-Hardy F. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. J Urol. 2010 May;183(5):1892-8. doi: 10.1016/j.juro.2010.01.012. Epub 2010 Mar 29.</citation>
    <PMID>20303119</PMID>
  </reference>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2007</study_first_submitted>
  <study_first_submitted_qc>February 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2007</study_first_posted>
  <results_first_submitted>October 5, 2009</results_first_submitted>
  <results_first_submitted_qc>December 8, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 11, 2010</results_first_posted>
  <last_update_submitted>June 1, 2010</last_update_submitted>
  <last_update_submitted_qc>June 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sr Manager Clinical Trial Registry</name_title>
    <organization>Astellas Pharma US, Inc</organization>
  </responsible_party>
  <keyword>Solifenacin succinate</keyword>
  <keyword>Oxybutynin immediate release</keyword>
  <keyword>Xerostomia</keyword>
  <keyword>Overactive bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
    <mesh_term>Oxybutynin</mesh_term>
    <mesh_term>Mandelic Acids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Solifenacin</title>
          <description>Solifenacin succinate: 5 mg tablets, taken orally, once daily</description>
        </group>
        <group group_id="P2">
          <title>Oxybutynin IR</title>
          <description>Oxybutynin Immediate Release: 5 mg capsules, taken orally, 3 times a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68">Data represents Intention To Treat(ITT) Population: All randomized subjects</participants>
                <participants group_id="P2" count="64">Data represents ITT Population: All randomized subjects</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Solifenacin</title>
          <description>Solifenacin succinate: 5 mg tablets, taken orally, once daily</description>
        </group>
        <group group_id="B2">
          <title>Oxybutynin IR</title>
          <description>Oxybutynin Immediate Release: 5 mg capsules, taken orally, 3 times a day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
            <count group_id="B2" value="64"/>
            <count group_id="B3" value="132"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aboriginal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects Reporting Incidence of Dry Mouth as an Adverse Event</title>
        <description>The number of subjects reporting incidence of dry mouth as an adverse event (AE) following direct questioning at each patient follow-up visit</description>
        <time_frame>8 weeks</time_frame>
        <population>Data represents ITT Population: all randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Solifenacin</title>
            <description>Solifenacin succinate: 5 mg tablets, taken orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Oxybutynin IR</title>
            <description>Oxybutynin Immediate Release: 5 mg capsules, taken orally, 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Reporting Incidence of Dry Mouth as an Adverse Event</title>
          <description>The number of subjects reporting incidence of dry mouth as an adverse event (AE) following direct questioning at each patient follow-up visit</description>
          <population>Data represents ITT Population: all randomized subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Severity of Dry Mouth Reported as an Adverse Event</title>
        <description>The number of subjects reporting dry mouth at each severity level when dry mouth was reported as an Adverse Event (AE).
Dry mouth severity was categorized as &quot;mild&quot; (relieved with fluid/hard candy), &quot;moderate&quot; (dry mouth and throat with no difficulty swallowing solid food/water) &amp; &quot;severe&quot; (very dry mouth &amp; throat, difficulty swallowing solid food without water)</description>
        <time_frame>8 weeks</time_frame>
        <population>Data represents ITT Population: all randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Solifenacin</title>
            <description>Solifenacin succinate: 5 mg tablets, taken orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Oxybutynin IR</title>
            <description>Oxybutynin Immediate Release: 5 mg capsules, taken orally, 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>The Severity of Dry Mouth Reported as an Adverse Event</title>
          <description>The number of subjects reporting dry mouth at each severity level when dry mouth was reported as an Adverse Event (AE).
Dry mouth severity was categorized as &quot;mild&quot; (relieved with fluid/hard candy), &quot;moderate&quot; (dry mouth and throat with no difficulty swallowing solid food/water) &amp; &quot;severe&quot; (very dry mouth &amp; throat, difficulty swallowing solid food without water)</description>
          <population>Data represents ITT Population: all randomized subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <p_value_desc>P-value represents overall comparison of severity of dry mouth.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Micturition Frequency as Reported in Subject 3-day Diary</title>
        <description>Subjects were instructed to complete the diary in the 3 day period immediately proceding the visit. Subjects recorded each micturition or instance of passing urine in the toliet.
The mean was calculated for each time point as the average of the day 1-3 measurements from the associated 3 day diary. Change from baseline was calculated as Week 8- Baseline.</description>
        <time_frame>Baseline and 8 Weeks</time_frame>
        <population>Data represents ITT Population: all randomized subjects. The numbers of subjects for each time point are noted in the category titles. Data for week 8 and Change from Baseline to week 8 includes all subjects who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Solifenacin</title>
            <description>Solifenacin succinate: 5 mg tablets, taken orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Oxybutynin IR</title>
            <description>Oxybutynin Immediate Release: 5 mg capsules, taken orally, 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Micturition Frequency as Reported in Subject 3-day Diary</title>
          <description>Subjects were instructed to complete the diary in the 3 day period immediately proceding the visit. Subjects recorded each micturition or instance of passing urine in the toliet.
The mean was calculated for each time point as the average of the day 1-3 measurements from the associated 3 day diary. Change from baseline was calculated as Week 8- Baseline.</description>
          <population>Data represents ITT Population: all randomized subjects. The numbers of subjects for each time point are noted in the category titles. Data for week 8 and Change from Baseline to week 8 includes all subjects who completed the study</population>
          <units>Micturitions per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in micturition frequency at 8 wks(N=52; 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="3.3"/>
                    <measurement group_id="O2" value="-3.1" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Micturition frequency at Baseline (N=68; 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="3.2"/>
                    <measurement group_id="O2" value="12.5" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Micturition frequency at 8 weeks (N=52; 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" spread="3.7"/>
                    <measurement group_id="O2" value="9.0" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urgency Episodes as Reported in Subject 3-day Diary</title>
        <description>Subjects were instructed to complete the diary in the 3 day period immediately preceding the visit. Subjects recorded each urgency episode or instance of strong desire to pass urine.
The mean was calculated for each time point as the average of the day 1-3 measurements from the associated 3 day diary. Change from Baseline was calculated as Week 8- Baseline.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Data represents ITT Population: all randomized subjects. The numbers of subjects for each time point are noted in the category titles. Data for week 8 and Change from Baseline to week 8 includes all subjects who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Solifenacin</title>
            <description>Solifenacin succinate: 5 mg tablets, taken orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Oxybutynin IR</title>
            <description>Oxybutynin Immediate Release: 5 mg capsules, taken orally, 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urgency Episodes as Reported in Subject 3-day Diary</title>
          <description>Subjects were instructed to complete the diary in the 3 day period immediately preceding the visit. Subjects recorded each urgency episode or instance of strong desire to pass urine.
The mean was calculated for each time point as the average of the day 1-3 measurements from the associated 3 day diary. Change from Baseline was calculated as Week 8- Baseline.</description>
          <population>Data represents ITT Population: all randomized subjects. The numbers of subjects for each time point are noted in the category titles. Data for week 8 and Change from Baseline to week 8 includes all subjects who completed the study</population>
          <units>urgency episodes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in urgency episodes at 8 weeks (N=52; 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.65" spread="4.54"/>
                    <measurement group_id="O2" value="-3.70" spread="3.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urgency episodes at Baseline (N= 68; 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="3.98"/>
                    <measurement group_id="O2" value="6.6" spread="4.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urgency episodes at 8 weeks (N=52; 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="5.04"/>
                    <measurement group_id="O2" value="2.1" spread="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Solifenacin</title>
          <description>Solifenacin succinate: 5 mg tablets, taken orally, once daily</description>
        </group>
        <group group_id="E2">
          <title>Oxybutynin IR</title>
          <description>Oxybutynin Immediate Release: 5 mg capsules, taken orally, 3 times a day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>fracture, right foot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cervical adenocarcinoma in situ</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4.5</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="68"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="25" subjects_affected="24" subjects_at_risk="68"/>
                <counts group_id="E2" events="56" subjects_affected="53" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="medDRA 9.0">Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Dry throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PIs may not present or publish data prior to publication of the multicenter data or 12 months have elapsed following database lock.
Sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of up to 90 days from the time submitted to the sponsor for review.
PIs may not engage in contacts with the media related to the study, study interventions or data without prior written consent.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The relatively high incidence of AEs, specifically dry mouth, in both groups may be a result of the direct questioning methodology used. Subjects were also informed the primary objectives were the relative frequency and severity of dry mouth.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Astellas Medical Monitor</name_or_title>
      <organization>Astellas Pharma Global Development</organization>
      <email>ClinicalTrials@us.astellas.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

